HighTower Advisors LLC Has $84.89 Million Holdings in Colgate-Palmolive (NYSE:CL)

HighTower Advisors LLC lessened its position in Colgate-Palmolive (NYSE:CL) by 3.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 933,828 shares of the company’s stock after selling 36,212 shares during the period. HighTower Advisors LLC owned approximately 0.11% of Colgate-Palmolive worth $84,894,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in CL. FMR LLC lifted its holdings in shares of Colgate-Palmolive by 65.6% in the third quarter. FMR LLC now owns 6,749,275 shares of the company’s stock valued at $700,642,000 after purchasing an additional 2,674,807 shares in the last quarter. AMF Tjanstepension AB lifted its holdings in shares of Colgate-Palmolive by 1,088.8% in the fourth quarter. AMF Tjanstepension AB now owns 2,569,394 shares of the company’s stock valued at $233,584,000 after purchasing an additional 2,353,268 shares in the last quarter. Barclays PLC lifted its holdings in shares of Colgate-Palmolive by 38.7% in the third quarter. Barclays PLC now owns 7,644,189 shares of the company’s stock valued at $793,542,000 after purchasing an additional 2,132,747 shares in the last quarter. State Street Corp lifted its holdings in shares of Colgate-Palmolive by 3.8% in the third quarter. State Street Corp now owns 48,436,276 shares of the company’s stock valued at $5,028,170,000 after purchasing an additional 1,784,411 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Colgate-Palmolive in the fourth quarter valued at approximately $132,405,000. Institutional investors and hedge funds own 80.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CL shares. Stifel Nicolaus dropped their target price on Colgate-Palmolive from $95.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, February 3rd. Morgan Stanley dropped their target price on Colgate-Palmolive from $111.00 to $104.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Raymond James reiterated an “outperform” rating and set a $105.00 price target (down from $110.00) on shares of Colgate-Palmolive in a report on Monday, February 3rd. JPMorgan Chase & Co. dropped their price target on Colgate-Palmolive from $103.00 to $97.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $101.00 price target on shares of Colgate-Palmolive in a report on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Colgate-Palmolive presently has an average rating of “Moderate Buy” and a consensus target price of $101.61.

Colgate-Palmolive Stock Performance

Shares of CL opened at $90.71 on Thursday. The firm has a market cap of $73.61 billion, a PE ratio of 25.77, a PEG ratio of 4.20 and a beta of 0.40. The stock’s fifty day moving average price is $89.03 and its two-hundred day moving average price is $94.96. The company has a debt-to-equity ratio of 13.40, a current ratio of 0.92 and a quick ratio of 0.58. Colgate-Palmolive has a 1 year low of $85.32 and a 1 year high of $109.30.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, January 31st. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.01. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. During the same period in the previous year, the firm earned $0.87 earnings per share. On average, equities research analysts forecast that Colgate-Palmolive will post 3.75 EPS for the current year.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.